XGN PE Ratio & Valuation,Is XGN Overvalued

XGN Relative Valuation

XGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XGN is overvalued; if below, it's undervalued.

Historical Valuation

Exagen Inc (XGN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.35. The fair price of Exagen Inc (XGN) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：7.03

Fair

-12.24

-80.03

EV/EBITDA

Exagen Inc. (XGN) has a current EV/EBITDA of -80.03. The 5-year average EV/EBITDA is -13.96. The thresholds are as follows: Strongly Undervalued below -72.21, Undervalued between -72.21 and -43.09, Fairly Valued between 15.16 and -43.09, Overvalued between 15.16 and 44.28, and Strongly Overvalued above 44.28. The current Forward EV/EBITDA of -80.03 falls within the Strongly Undervalued range.

-20.22

EV/EBIT

Exagen Inc. (XGN) has a current EV/EBIT of -20.22. The 5-year average EV/EBIT is -5.51. The thresholds are as follows: Strongly Undervalued below -21.17, Undervalued between -21.17 and -13.34, Fairly Valued between 2.32 and -13.34, Overvalued between 2.32 and 10.15, and Strongly Overvalued above 10.15. The current Forward EV/EBIT of -20.22 falls within the Undervalued range.

2.15

Exagen Inc. (XGN) has a current PS of 2.15. The 5-year average PS is 2.06. The thresholds are as follows: Strongly Undervalued below -0.97, Undervalued between -0.97 and 0.54, Fairly Valued between 3.57 and 0.54, Overvalued between 3.57 and 5.08, and Strongly Overvalued above 5.08. The current Forward PS of 2.15 falls within the Historic Trend Line -Fairly Valued range.

-29.52

P/OCF

Exagen Inc. (XGN) has a current P/OCF of -29.52. The 5-year average P/OCF is -9.49. The thresholds are as follows: Strongly Undervalued below -40.02, Undervalued between -40.02 and -24.76, Fairly Valued between 5.77 and -24.76, Overvalued between 5.77 and 21.03, and Strongly Overvalued above 21.03. The current Forward P/OCF of -29.52 falls within the Undervalued range.

-45.39

P/FCF

Exagen Inc. (XGN) has a current P/FCF of -45.39. The 5-year average P/FCF is -10.39. The thresholds are as follows: Strongly Undervalued below -46.02, Undervalued between -46.02 and -28.21, Fairly Valued between 7.43 and -28.21, Overvalued between 7.43 and 25.24, and Strongly Overvalued above 25.24. The current Forward P/FCF of -45.39 falls within the Undervalued range.

Exagen Inc (XGN) has a current Price-to-Book (P/B) ratio of 8.72. Compared to its 3-year average P/B ratio of 4.73 , the current P/B ratio is approximately 84.42% higher. Relative to its 5-year average P/B ratio of 3.71, the current P/B ratio is about 134.97% higher. Exagen Inc (XGN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -43.49%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -35.95% , the current FCF yield is about -100.00% lower.

8.72

P/B

Median3y

4.73

Median5y

3.71

-6.82

FCF Yield

Median3y

-43.49

Median5y

-35.95

Competitors Valuation Multiple

The average P/S ratio for XGN's competitors is , providing a benchmark for relative valuation. Exagen Inc Corp (XGN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 37.87%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of XGN increased by 71.46% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 12.51M to 17.24M.

The secondary factor is the P/E Change, contributed 31.35%to the performance.

Overall, the performance of XGN in the past 1 year is driven by Revenue Growth. Which is more sustainable.

37.87%

12.51M → 17.24M

Revenue Growth

2.24%

-40.20 → -41.10

Margin Expansion

31.35%

-5.70 → -7.48

P/E Change

71.46%

4.10 → 7.03

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Exagen Inc (XGN) currently overvalued or undervalued?

What is Exagen Inc (XGN) fair value?

XGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Exagen Inc (XGN) is between NaN to NaN according to relative valuation methord.

How does XGN's valuation metrics compare to the industry average?

What is the current P/B ratio for Exagen Inc (XGN) as of Dec 16 2025?

As of Dec 16 2025, Exagen Inc (XGN) has a P/B ratio of 8.72. This indicates that the market values XGN at 8.72 times its book value.

What is the current FCF Yield for Exagen Inc (XGN) as of Dec 16 2025?

As of Dec 16 2025, Exagen Inc (XGN) has a FCF Yield of 0.00%. This means that for every dollar of Exagen Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Exagen Inc (XGN) as of Dec 16 2025?

As of Dec 16 2025, Exagen Inc (XGN) has a Forward P/E ratio of -12.24. This means the market is willing to pay $-12.24 for every dollar of Exagen Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Exagen Inc (XGN) as of Dec 16 2025?

As of Dec 16 2025, Exagen Inc (XGN) has a Forward P/S ratio of 0.00. This means the market is valuing XGN at $0.00 for every dollar of expected revenue over the next 12 months.

XGN Valuation